News
The U.S. Food and Drug Administration on Thursday publicly shared over 200 archived so-called complete response letters ...
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.
FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.
By Stephanie Brown HealthDay ReporterTHURSDAY, July 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
On July 10, 2025, the Food and Drug Administration (FDA) announced that it had published more than 200 complete response letters (CRLs), in ...
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
3d
Pharmaceutical Technology on MSNUltragenyx receives complete response letter for UX111 BLAThe FDA's request stems from observations made during recent inspections of Ultragenyx's manufacturing facilities.
The U.S. FDA publishes over 200 complete response letters to enhance transparency within the agency. Read more here.
While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results